BioNTech (NASDAQ:BNTX) Stock Rating Reaffirmed by HC Wainwright

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $113.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 14.14% from the company’s previous close.

BNTX has been the topic of a number of other reports. Evercore ISI assumed coverage on shares of BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 price target on the stock. UBS Group dropped their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. BMO Capital Markets decreased their price objective on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. Finally, The Goldman Sachs Group lowered their price objective on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $111.70.

BioNTech Stock Down 3.2 %

NASDAQ:BNTX opened at $99.00 on Friday. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $85.21 and a 12-month high of $125.83. The stock’s fifty day simple moving average is $90.83 and its 200-day simple moving average is $95.91. The firm has a market capitalization of $23.54 billion, a P/E ratio of 198.00 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. Equities research analysts expect that BioNTech will post -1.99 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors have recently added to or reduced their stakes in the company. Raymond James & Associates increased its stake in shares of BioNTech by 5.6% during the 3rd quarter. Raymond James & Associates now owns 5,579 shares of the company’s stock worth $606,000 after purchasing an additional 298 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of BioNTech by 186.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 855 shares of the company’s stock worth $93,000 after acquiring an additional 556 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in BioNTech by 11.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,725 shares of the company’s stock valued at $296,000 after purchasing an additional 279 shares during the last quarter. Fox Run Management L.L.C. bought a new position in BioNTech during the third quarter worth $861,000. Finally, Harbor Advisors LLC bought a new position in shares of BioNTech in the third quarter valued at about $217,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.